Melanoma ECOG3612

April 27, 2017

Sponsor: National Cancer Institute (NCI)

Number: ECOG3612

Eligible patients who enroll in the study will be randomly assigned (by chance) to this phase II trial (Phase II: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety) which studies how well Ipilimumab with or without Bevacizumab works in treating patients with stage III-IV melanoma that cannot be removed by surgery. Monoclonal antibodies, such as Ipilimumab and Bevacizumab, block tumor growth in different ways by targeting certain cells.

Who’s eligible:

  • Patient must have a confirmed diagnosis of low tumor burden, CD20-positive follicular lymphoma, and Ann Arbor Stage II, III, or IV (This stage depends on both the place where the malignant tissue is located and on systemic symptoms due to the lymphoma).
  • This study is for patients age 18 and older

Available at: Backus Hospital- Eastern Connecticut Hematology and Oncology.

Cancer Clinical Research Office